Urinary biomarkers of mycobacterial load and treatment response in pulmonary tuberculosis

被引:8
|
作者
Xia, Qianjing [1 ]
Lee, Myung Hee [2 ]
Walsh, Kathleen F. [2 ,3 ]
McAulay, Kathrine [2 ,4 ]
Bean, James M. [5 ]
Fitzgerald, Daniel W. [2 ,3 ,6 ]
Dupnik, Kathryn M. [2 ,3 ]
Johnson, Warren D. [2 ,3 ,6 ]
Pape, Jean W. [2 ,6 ]
Rhee, Kyu Y. [2 ,3 ,4 ]
Isa, Flonza [3 ]
机构
[1] Weill Cornell Med Coll, New York, NY USA
[2] Weill Cornell Med, Ctr Global Hlth, New York, NY 10065 USA
[3] Weill Cornell Med, Dept Med, 1300 York Ave,Room A-421, New York, NY 10065 USA
[4] Weill Cornell Med, Dept Microbiol & Immunol, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Ctr GHESKIO, Port Au Prince, Haiti
关键词
N-1; N-12-DIACETYLSPERMINE; N-8-DIACETYLSPERMIDINE; DIAGNOSIS; SYSTEMS; HOST; TIME;
D O I
10.1172/jci.insight.136301
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BACKGROUND. Control of the tuberculosis (TB) pandemic remains hindered in part by a lack of simple and accurate measures of treatment efficacy, as current gold standard markers rely on sputum-based assays that are slow and challenging to implement. However, previous work identified urinary N-1, N-12-diacetylspermine (DiAcSpm), neopterin, hydroxykynurenine, N-acetylhexosamine, ureidopropionic acid, sialic acid, and mass-to-charge ratio (m/z) 241.0903 as potential biomarkers of active pulmonary TB (ATB). Here, we evaluated their ability to serve as biomarkers of TB treatment response and mycobacterial load. METHODS. We analyzed urine samples prospectively collected from 2 cohorts with ATB. A total of 34 study participants from African countries treated with first-line TB therapy rifampin, isoniazid, pyrazinamide, and ethambutol (HRZE) were followed for 1 year, and 35 participants from Haiti treated with either HRZE or an experimental drug were followed for 14 days. Blinded samples were analyzed by untargeted HPLC-coupled high-resolution TOF-mass spectrometry. RESULTS. Urinary levels of all 7 molecules significantly decreased by week 26 of successful treatment (P = 0.01 to P < 0.0001) and positively correlated with sputum mycobacterial load (P < 0.0001). Urinary DiAcSpm levels decreased significantly in participants treated with HRZE as early as 14 days (P < 0.0001) but remained unchanged in cases of ineffective therapy (P = 0.14). CONCLUSION. Urinary DiAcSpm, neopterin, hydroxykynurenine, N-acetylhexosamine, ureidopropionic acid, sialic acid, and m/z 241.0903 reductions correlated with successful anti-TB treatment and sputum mycobacterial load. Urinary DiAcSpm levels exhibited reductions capable of differentiating treatment success from failure as early as 2 weeks after the initiation of chemotherapy, advocating its further development as a potentially simple, noninvasive biomarker for assessing treatment response and bacterial load.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Mycobacterial Lineages Causing Pulmonary and Extrapulmonary Tuberculosis, Ethiopia
    Firdessa, Rebuma
    Berg, Stefan
    Hailu, Elena
    Schelling, Esther
    Gumi, Balako
    Erenso, Girume
    Gadisa, Endalamaw
    Kiros, Teklu
    Habtamu, Meseret
    Hussein, Jemal
    Zinsstag, Jakob
    Robertson, Brian D.
    Ameni, Gobena
    Lohan, Amanda J.
    Loftus, Brendan
    Comas, Inaki
    Gagneux, Sebastien
    Tschopp, Rea
    Yamuah, Lawrence
    Hewinson, Glyn
    Gordon, Stephen V.
    Young, Douglas B.
    Aseffa, Abraham
    EMERGING INFECTIOUS DISEASES, 2013, 19 (03) : 460 - 463
  • [32] Messenger RNA as a marker of treatment response in pulmonary tuberculosis
    Perrin, FMR
    Parsons, YN
    Breen, RAM
    Islam, J
    McHugh, TD
    Lipman, MCI
    Gillespie, SH
    THORAX, 2005, 60 : II44 - II44
  • [33] Urinary Biomarkers in the Prediction of Prognosis and Treatment Response in IgA Nephropathy
    Neuhaus, Julia
    Bauer, Frederic
    Fitzner, Christina
    Hilgers, Ralf-Dieter
    Seibert, Felix
    Babel, Nina
    Doevelaar, Adrian
    Eitner, Frank
    Floege, Juergen
    Rauen, Thomas
    Westhoff, Timm H.
    KIDNEY & BLOOD PRESSURE RESEARCH, 2018, 43 (05): : 1563 - 1572
  • [34] Urinary biomarkers for monitoring treatment response in neuroblastoma patients.
    Amano, Hizuru
    Hinoki, Akinari
    Uchida, Hiroo
    Yokota, Kazuki
    Ishigaki, Takashi
    Sakairi, Minoru
    Abe, Mayumi
    Takahashi, Yoshiyuki
    Narita, Atsushi
    Tainaka, Takahisa
    Shirota, Chiyoe
    Sumida, Wataru
    Makita, Satoshi
    Takimoto, Aitaro
    Kano, Yoko
    Yasui, Akihiro
    Okamoto, Masamune
    Nakagawa, Yoichi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] THE TREATMENT OF URINARY TUBERCULOSIS
    WONG, SH
    LAU, WY
    POON, GP
    FAN, ST
    HO, KK
    YIU, TF
    CHAN, SL
    JOURNAL OF UROLOGY, 1984, 131 (02): : 297 - 301
  • [36] Pulmonary Non-tuberculous Mycobacterial Colonization Versus Disease Diagnosed During Tuberculosis Treatment
    Ganninger, A.
    Goldstein, D.
    Kumar, K.
    Bennett, S. Cooper
    Robinson, C.
    Fennelly, K. P.
    Anidi, I. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [37] Volatile biomarkers of pulmonary tuberculosis in the breath
    Phillips, Michael
    Cataneo, Renee N.
    Condos, Rany
    Erickson, Gerald A. Ring
    Greenberg, Joel
    La Bombardi, Vincent
    Munawar, Muhammad I.
    Tietje, Olaf
    TUBERCULOSIS, 2007, 87 (01) : 44 - 52
  • [38] Local Pulmonary Immunological Biomarkers in Tuberculosis
    Morrison, Hazel
    McShane, Helen
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [39] Breath biomarkers of active pulmonary tuberculosis
    Phillips, Michael
    Basa-Dalay, Victoria
    Bothamley, Graham
    Cataneo, Renee N.
    Lam, Phung Kim
    Natividad, Maria Piedad R.
    Schmitt, Peter
    Wai, James
    TUBERCULOSIS, 2010, 90 (02) : 145 - 151
  • [40] The urinary acidity variations of pulmonary tuberculosis
    Goiffon, R
    Blasko, R
    COMPTES RENDUS DES SEANCES DE LA SOCIETE DE BIOLOGIE ET DE SES FILIALES, 1928, 98 : 1393 - 1393